慢性粒细胞白血病酪氨酸激酶抑制剂耐药的研究进展

Progress of tyrosine kinase inhibitor resistance in chronic myeloid leukemia

慢性粒细胞白血病(CML)是一种骨髓造血干细胞克隆性增殖形成的恶性肿瘤。随着对疾病认识的提高以及新型药物的面市,90%以上的CML患者可以获得长期生存,然而仍有少部分患者耐药。文章分析了应用酪氨酸激酶抑制剂(TKI)治疗CML患者发生耐药的机制,以及ABL激酶区突变的特征。

Chronic myeloid leukemia(CML)is a malignant tumor formed by clonal proliferation of bone marrow hematopoietic stem cells.With the improvement of disease awareness and the introduction of new drugs,more than 90%of CML patients can achieve long-term survival.However,a few patients still show drug resistance.This article reviews the mechanism of drug resistance in CML patients treated with tyrosine kinase inhibitor(TKI)and the characteristics of ABL kinase region mutation.